Physician profile
John Lewandowski
NPI 1053773879
$1,675.01
in general payments reported to CMS, 2019-2025
10 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $1,268 · 2023: $15.64 · 2024: $151 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $284.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,197.24 | 2022-2024 | |
| Acera Surgical, INC. | $239.80 | 2021-2024 | Restrata Wound Matrix |
| Vertex Pharmaceuticals Incorporated | $52.54 | 2024-2025 | |
| Smith+Nephew, INC. | $35.08 | 2024 | Pico 14, Collagenase Santyl |
| Tela Bio, INC. | $34.37 | 2024 | Ovitex 2s |
| Medical Device Business Services, INC. | $31.92 | 2021 | |
| Polynovo North America LLC | $23.44 | 2025 | Novosorb Btm |
| Aroa Biosurgery Incorporated | $22.76 | 2025 | |
| Medtronic, INC. | $19.42 | 2025 | Transorb |
| Solventum Corporation | $18.44 | 2025 | V.A.C. Veraflo, Prevena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lewandowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.